Regulatory delays in bone marrow transplant approval
Government approval for bone marrow transplant unit is delayed due to procedural issues, pushing revenue contribution to FY28.
medium · analyst_questionAsarfi Hospital Ltd — Q4 FY26
Asarfi Hospital reported Q4 FY26 consolidated revenue of 45.2 crore (+29% YoY), EBITDA of 7.7 crore (17% margin), and PAT of 3.9 crore (+9% YoY).
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Volatility in government scheme reimbursements
Changes in government scheme approval systems caused a decline in cancer patient volumes in Q4; future volatility could impact revenue.
medium · analyst_questionElevated receivables and working capital pressure
Receivables aging of 6-7 months due to delayed government reimbursements may keep working capital elevated.
medium · analyst_questionExecution risk in aggressive growth targets
The FY27 revenue target of 260 crore and 500+ bed capacity by 2028 appear aggressive given current run-rate and regulatory hurdles.
high · data_observation